- Home
- SRPT
as 06-20-2025 3:41pm EST
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 1997 |
| Target Price: | $70.92 | AVG Volume (30 days): | 6.5M |
| Analyst Decision: | Buy | Number of Analysts: | 26 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.30 - $173.25 | Next Earning Date: | 08-06-2025 |
| Revenue: | $2,233,371,000 | Revenue Growth: | 59.15% |
| Revenue Growth (this year): | 26.87% | Revenue Growth (next year): | 3.15% |
Latest Sarepta Therapeutics Inc. (DE) News
SRPT Breaking Stock News: Dive into SRPT Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
William Blair Downgrades Sarepta Therapeutics to Market Perform From Outperform
StockStory
2 days ago
2 Growth Stocks with All-Star Potential and 1 to Ignore
TipRanks
2 days ago
SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls
Barrons.com
3 days ago
Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.
TipRanks
3 days ago
Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls
MT Newswires
3 days ago
Goldman Sachs Downgrades Sarepta Therapeutics to Neutral From Buy, Adjusts Price Target to $29 From $100
MT Newswires
3 days ago
TD Cowen Downgrades Sarepta Therapeutics to Hold From Buy, Cuts Price Target to $24 From $62
Simply Wall St.
4 days ago
Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation
Compare SRPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRPT Sarepta Therapeutics Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.